Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 694 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR What Is Scanxiety? How People With Cancer and Survivors Can Cope October 28, 2021 High School Students Put Together Fundraiser for Teacher Diagnosed with Breast... December 17, 2020 Celebrating 75 years of NHS cancer care July 5, 2023 Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... September 24, 2020 Load more HOT NEWS Boy Asks Mom Fighting Cancer To Take Off Her Turban So... Woman Showed Up To Their Wedding And Stole All Their Gifts.... Alex Trebek Has Completed Chemo And Will Be Back For The... Darolutamide Maintenance Improves Outcomes in Patients with mCRPC Who Were Previously...
